These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 18260117)

  • 1. Descriptive epidemiology of childhood Langerhans cell histiocytosis in France, 2000-2004.
    Guyot-Goubin A; Donadieu J; Barkaoui M; Bellec S; Thomas C; Clavel J
    Pediatr Blood Cancer; 2008 Jul; 51(1):71-5. PubMed ID: 18260117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II study in children and adults under 40 years with newly diagnosed Langerhans cell histiocytosis: protocol for an LCH-19-MSMFB clinical trial in Japan.
    Ono R; Sakamoto K; Kudo K; Sato A; Kudo K; Fujino H; Kawahara Y; Hashimoto H; Doi T; Yanagisawa R; Kawamata T; Miyazaki O; Nakazawa A; Ota Y; Kanegane H; Nakazawa Y; Horibe K; Saito AM; Manabe A; Usuki K; Kiyoi H; Morimoto A; Tojo A; Shioda Y
    BMJ Open; 2024 Jun; 14(6):e084159. PubMed ID: 38910000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Exploration of treatment in childhood Langerhans cell histiocytosis based on inflammatory and malignant symptoms: a pilot study.
    Lin HL; Zheng QQ; Huang RL; Hu R; Liu XD; Wang JY
    Orphanet J Rare Dis; 2024 Apr; 19(1):174. PubMed ID: 38654381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nationwide Study of Factors Impacting Survival Outcome and Consequences in Children with Reactivation/Refractory Langerhans Cell Histiocytosis.
    Monsereenusorn C; Suwannaying K; Buaboonnam J; Sathitsamitphong L; Techavichit P; Pakakasama S; Chainansamit SO; Anurathapan U; Komvilaisak P; Traivaree C; Sanpakit K; Charoenkwan P; Seksarn P
    Asian Pac J Cancer Prev; 2024 May; 25(5):1831-1839. PubMed ID: 38809656
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term outcomes among adults with Langerhans cell histiocytosis.
    Goyal G; Acosta-Medina AA; Abeykoon JP; Dai C; Ravindran A; Vassallo R; Ryu JH; Shah MV; Bennani NN; Young JR; Bach CR; Ruan GJ; Zanwar S; Tobin WO; Koster MJ; Davidge-Pitts CJ; Gruber LM; Dasari S; Rech KL; Go RS
    Blood Adv; 2023 Nov; 7(21):6568-6578. PubMed ID: 37698994
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland.
    Salotti JA; Nanduri V; Pearce MS; Parker L; Lynn R; Windebank KP
    Arch Dis Child; 2009 May; 94(5):376-80. PubMed ID: 19060008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidence of Langerhans cell histiocytosis in children: a population-based study.
    Stålemark H; Laurencikas E; Karis J; Gavhed D; Fadeel B; Henter JI
    Pediatr Blood Cancer; 2008 Jul; 51(1):76-81. PubMed ID: 18266220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.
    Gadner H; Minkov M; Grois N; Pötschger U; Thiem E; Aricò M; Astigarraga I; Braier J; Donadieu J; Henter JI; Janka-Schaub G; McClain KL; Weitzman S; Windebank K; Ladisch S;
    Blood; 2013 Jun; 121(25):5006-14. PubMed ID: 23589673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Recurrent BRAF mutations in Langerhans cell histiocytosis.
    Badalian-Very G; Vergilio JA; Degar BA; MacConaill LE; Brandner B; Calicchio ML; Kuo FC; Ligon AH; Stevenson KE; Kehoe SM; Garraway LA; Hahn WC; Meyerson M; Fleming MD; Rollins BJ
    Blood; 2010 Sep; 116(11):1919-23. PubMed ID: 20519626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Langerhans'-cell histiocytosis in adults.
    Baumgartner I; von Hochstetter A; Baumert B; Luetolf U; Follath F
    Med Pediatr Oncol; 1997 Jan; 28(1):9-14. PubMed ID: 8950330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pathogenesis of Langerhans cell histiocytosis.
    Badalian-Very G; Vergilio JA; Fleming M; Rollins BJ
    Annu Rev Pathol; 2013 Jan; 8():1-20. PubMed ID: 22906202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells.
    Allen CE; Li L; Peters TL; Leung HC; Yu A; Man TK; Gurusiddappa S; Phillips MT; Hicks MJ; Gaikwad A; Merad M; McClain KL
    J Immunol; 2010 Apr; 184(8):4557-67. PubMed ID: 20220088
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Langerhans-Cell Histiocytosis.
    Allen CE; Merad M; McClain KL
    N Engl J Med; 2018 Aug; 379(9):856-868. PubMed ID: 30157397
    [No Abstract]   [Full Text] [Related]  

  • 14. Langerhans cell histiocytosis in children: History, classification, pathobiology, clinical manifestations, and prognosis.
    Krooks J; Minkov M; Weatherall AG
    J Am Acad Dermatol; 2018 Jun; 78(6):1035-1044. PubMed ID: 29754885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages.
    Emile JF; Abla O; Fraitag S; Horne A; Haroche J; Donadieu J; Requena-Caballero L; Jordan MB; Abdel-Wahab O; Allen CE; Charlotte F; Diamond EL; Egeler RM; Fischer A; Herrera JG; Henter JI; Janku F; Merad M; Picarsic J; Rodriguez-Galindo C; Rollins BJ; Tazi A; Vassallo R; Weiss LM;
    Blood; 2016 Jun; 127(22):2672-81. PubMed ID: 26966089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adult disseminated Langerhans cell histiocytosis: incidence, racial disparities and long-term outcomes.
    Goyal G; Shah MV; Hook CC; Wolanskyj AP; Call TG; Rech KL; Go RS
    Br J Haematol; 2018 Aug; 182(4):579-581. PubMed ID: 28653448
    [No Abstract]   [Full Text] [Related]  

  • 17. Langerhans cell histiocytosis in adults: Advances in pathophysiology and treatment.
    Kobayashi M; Tojo A
    Cancer Sci; 2018 Dec; 109(12):3707-3713. PubMed ID: 30281871
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Late outcomes in children with Langerhans cell histiocytosis.
    Chow TW; Leung WK; Cheng FWT; Kumta SM; Chu WCW; Lee V; Shing MMK; Li CK
    Arch Dis Child; 2017 Sep; 102(9):830-835. PubMed ID: 28442470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.
    Berres ML; Lim KP; Peters T; Price J; Takizawa H; Salmon H; Idoyaga J; Ruzo A; Lupo PJ; Hicks MJ; Shih A; Simko SJ; Abhyankar H; Chakraborty R; Leboeuf M; Beltrão M; Lira SA; Heym KM; Bigley V; Collin M; Manz MG; McClain K; Merad M; Allen CE
    J Exp Med; 2014 Apr; 211(4):669-83. PubMed ID: 24638167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Langerhans cell histiocytosis: 40 years' experience.
    Maria Postini A; del Prever AB; Pagano M; Rivetti E; Berger M; Asaftei SD; Barat V; Andreacchio A; Fagioli F
    J Pediatr Hematol Oncol; 2012 Jul; 34(5):353-8. PubMed ID: 22627580
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.